In patients with type 2 diabetes (T2D) and metabolic dysfunction–associated steatotic liver disease (MASLD), the risk for major liver outcomes appears similar with dipeptidyl peptidase 4 (DPP-4) and ...
Type 2 diabetes is characterised by progressive insulin secretory dysfunction and insulin resistance, which together drive chronic hyperglycaemia and associated microvascular and macrovascular ...